These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://keithjyjz939661.answerblogs.com/39500142/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide